Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial

Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial

Recce Pharmaceuticals — R327 progressing in rapid infusion study

Recce Pharmaceuticals — R327 progressing in rapid infusion study

Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial

Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial

Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds

Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds

Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections

Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections

Recce Pharmaceuticals awarded Australian patent for lead anti-infectives

Recce Pharmaceuticals awarded Australian patent for lead anti-infectives

Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule

Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule

Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial

Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial

Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study

Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study

Recce Pharmaceuticals receives A$801,604 in R&D rebate advance

Recce Pharmaceuticals receives A$801,604 in R&D rebate advance